Interleukin-2, human (hIL-2)
ROCHE/HIL2-RO - recombinant (E. coli)
Synonym: hIL-2; human interleukin-2
Product Type: Chemical
Interleukin-2, human (hIL-2)
| assay | 95% (SDS-PAGE) |
| biological source | human |
| concentration | 10-20U/ml |
| form | solution |
| impurities | <0.1 EU/μg |
| manufacturer/tradename | Roche |
| mol wt | (15,000 Da) |
| packaging | pkg of 10,000 U (10799068001 [5 μg, 50 ml]) |
| pkg of 10,000 U (11011456001 [5 μg, 1 ml]) | |
| pkg of 50,000 U (11147528001 [25 μg, 5 ml]) | |
| potency | >2 x 10^6 units/mg EC50 |
| Quality Level | 100  |
| recombinant | expressed in E. coli |
| storage condition | avoid repeated freeze/thaw cycles |
| storage temp. | −20°C |
| UniProt accession no. | P60568  |
| Application: | Recombinant IL-2, human, allows: • The cultivation of human and murine IL-2 dependent T-cell lines and natural killer cell lines. • The proliferation of mitogen-activated T-lymphocytes and natural killer cells. • The establishment of human and murine thymocyte, splenocyte, or peripheral blood lymphocyte (PBL) derived T-cell lines. • The generation of human and murine lymphokine-activated killer (LAK) cells (1-11). • In vitro re-stimulation of lung cells obtained from mice. |
| Biochem/physiol Actions: | Interlekin-2 (IL-2) is a potent pro-inflammatory cytokine. It plays a protective role in autoimmune chronic inflammation, when present in low amounts. It is involved in maintaining immune homeostasis where it controls the cross-talk between T regulatory and T effector cells. Studies in acute myelogenous leukemia (AML) mice models show that antibody based delivery of IL-2 to targets present in tumor-linked vasculature results in antileukemic activity. |
| General description: | Recombinant Interleukin-2, human (hIL-2) is produced in E. coli and purified by standard chromatographic techniques. Solution in PBS and 1 mg/ml BSA, filtered through a 0.2 μm pore size membrane. |
| Other Notes: | For life science research only. Not for use in diagnostic procedures. |
| Physical form: | Solution in PBS and 1 mg/ml BSA, filtered through a 0.2 μm pore size membrane |
| Preparation Note: | Working concentration: 10 -20 U/ml Established IL-2-dependent T-cell lines usually require 10-20 U/ml. Add IL-2 to the freezing medium for IL-2 dependent cell lines. Working solution: Dilute the concentrated IL-2 solution (200 U/ml or 10,000 U/ml) with PBS or culture medium containing 1 mg/ml BSA or HSA (0.1%) or 1 to 10% serum. Storage conditions (working solution): -15 to -25 °C It is recommended to store the solution in aliquots at -15 to -25 °C. Note: Avoid repeated freezing and thawing. Specific activity/EC 50 : >2 x 106 U/mg <0.5 ng/ml (hIL-2, NIBSC, 1st international standard, 86/504), at least the same specific activity (EC50 ) compared to the indicated standard is guaranteed (19, 20). Human, recombinant IL-2 has the same biological activity in vitro as compared to human, natural IL-2 (15, 1–4). Recommended Method of Dilution: Dilute the concentrated IL-2 solution (200 U/ml or 10,000 U/ml) with PBS or culture medium containing 1 mg/ml BSA or HSA (0.1%) or 1–10% serum. Interleukin-2 (IL-2, also known as T-Cell Growth Factor, TCGF) is a lymphokine which is produced by lectin- or antigen-activated T-cells and plays an important immunoregulatory role. This factor, or lymphokine, was first identified by its ability to promote the long-term in vitro proliferation of activated T cells. It also promotes the generation and proliferation of cytotoxic T-cells, natural killer (NK) cells, and lymphokine- activated killer (LAK) cells (1–11). Recombinant human IL-2 allows the cultivation of human and murine IL-2-dependent T-cell lines and natural killer cell lines, the proliferation of mitogenactivated T-lymphocytes and natural killer cells, the establishment of human and murine thymocyte-, splenocyte-, or peripheral blood lymphocyte (PBL)- derived T-cell lines, and the generation of human and murine lymphokine-activated killer (LAK) cells (1-11). Established IL-2-dependant T-cell lines usually require 10-20 U/ml. Add IL-2 to the freezing medium for IL-2 dependant cell lines. |
| Quality: | Purity: >95% pure as determined by SDS-PAGE Endotoxin level: <0.1 EU/μg (LAL-test), <10 EU/ml (LAL-test) (1 EU corresponds to 0.1 ng) |
| Sequence: | Chain Length 134 AA |
| Sequence: | The primary structure of recombinant, IL-2, human is identical to that of natural, human IL-2 (one polypeptide chain, 133 amino acids), however, recombinant IL-2 has an extra methionine at the amino-terminus (one polypeptide chain, 134 amino acids) and is not glycosylated. Glycosylation is not essential for biological activity. |
| Specificity: | Species specificity: Recombinant IL-2, human is effective on mouse and human cells. |
| Unit Definition: | EC50 definition: The amount of hIL-2 that is required to support half-maximal stimulation of cell proliferation (XTT cleavage) with CTLL-2 cells (1 unit equals ≤0.5 ng). Unit Conversion: 1 BM unit = 3.25 NBSB units (natural IL-2)1 BM unit = 3.25 NBSB units (natural IL-2) |
| RIDADR | NONH for all modes of transport |
| WGK Germany | nwg |
| Flash Point(F) | No data available |
| Flash Point(C) | No data available |
| Purity | 95% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |